article thumbnail

AI continues to gain momentum in the biopharmaceutical industry in 2023

Pharmaceutical Technology

The report also suggested that Big Data was thought to be the most important partner to AI, in terms of introducing technology-related changes in the pharmaceutical sector (Figure 2). In addition to collaborating with AI-technology providers, pharma companies are also engaging in vertical integration.

Big Data 303
article thumbnail

What’s the next step in big data and AI?

Drug Discovery World

Big data and AI are all the rage. But, beyond these buzzwords and the quantity of data, what’s next for these powerful tools? His work provides insight into AI and big data in relation to pharma and drug discovery– now and in the future. “AI

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Synthetic control arms in clinical trials: Making it happen

pharmaphorum

Across the industry, pharma companies are turning to AI and real-world data to address many of the challenges of running clinical trials. David Clifton is professor of clinical machine learning in the Department of Engineering Science of the University of Oxford.

article thumbnail

Using technology to reassess the clinical trial landscape

pharmaphorum

Josh Sackman, president and co-founder of AppliedVR, and Web Sun, president and co-founder of Komodo Health, relay how their newly formed collaboration reshapes the clinical trial process by using data, helping to cut costs and allowing for evaluation of broader patient populations. .

article thumbnail

EMA pilot will see if clinical trial data should be digested ‘raw’

pharmaphorum

A pilot study has been launched by the EMA to see whether it is helpful for regulators to look at the ‘raw data’ from clinical trials submitted in support of new marketing application along with the usual structured analyses from sponsors.

article thumbnail

The DDW Podcast: 2023 in review

Drug Discovery World

Ng is working on critical challenges in clinical trials, specifically in planning and recruitment, and has been building innovative solutions designed to benefit patients and researchers – with a focus on efficiency, transparency and diversity in clinical development. Listen here. Listen here. Listen here.

article thumbnail

Pioneering access to complex generic products 

Drug Discovery World

Originator pharma companies are developing ever more complex products, which are transforming the medical landscape, but their cost places an increasing burden on healthcare budgets worldwide. Opportunities Originator pharma companies are developing more and more complex products these days.